- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- APC Sequencing and Deletion/Duplication
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCA Ashkenazi Jewish Screen
- BRCA Ashkenazi Jewish Screen with Reflex to BRCA Panel (BRCA1, BRCA2)
- BRCA Panel (BRCA1, BRCA2)
- BRCA Panel Plus
- BRCA1 and BRCA2 Deletion/Duplication
- BRCAvantage®, Rearrangements
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- CHEK2 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- CDH1 Sequencing and Deletion/Duplication
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Comprehensive Hereditary Cancer Panel
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diagnosis of Intestinal Parasites
- Donor Testing
- Drug Monitoring, Antidepressants, With Confirmation, Urine and Serum
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- FLT3 Mutation Analysis
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Breast Cancer Panel
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Cancer Single Site(s)
- Hereditary Colorectal Cancer Panel
- Hereditary Endocrine Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Li-Fraumeni Syndrome, TP53 Sequencing and Deletion/Duplication
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Lyme Disease Testing
- Lynch Syndrome Panel
- Lynch Syndrome, MLH1 Sequencing and Deletion/Duplication
- Lynch syndrome, MSH2 Sequencing and Deletion/Duplication (Including EPCAM)
- Lynch Syndrome, MSH6 Sequencing and Deletion/Duplication
- Lynch Syndrome, PMS2 Sequencing and Deletion/Duplication
- MEN1 Sequencing and Deletion/Duplication
- MUTYH Sequencing and Deletion/Duplication
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- NF1 Sequencing and Deletion/Duplication
- NAFLD Fibrosis Score
- Nevoid Basal Cell Carcinoma (NBCCS) (Gorlin) Syndrome Panel (PTCH1, SUFU)
- No FAQs found
- PALB2 Sequencing and Deletion/Duplication
- PTEN Sequencing and Deletion/Duplication
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Porphyria Testing
- Prothrombin Time with INR
- PTH, Intact and Calcium
- STK11 Sequencing and Deletion/Duplication
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- Tuberous Sclerosis Complex Panel (TSC1, TSC2)
- No FAQs found
- VHL Sequencing and Deletion/Duplication
- Varicella Zoster Virus Antibody (IgG)
- Vitamin D Testing
- von Willebrand Comprehensive Panel
- No FAQs found
- No FAQs found
HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)Test code(s) 94807(X), 94810(X)
Question 1. What is proviral DNA?
In infected cells, HIV-1 RNA is reverse-transcribed to DNA. The viral integrase enzyme then mediates the integration of the viral DNA into the chromosomes of the host cell. This integrated HIV DNA, known as proviral DNA, may remain latent or may be transcribed to produce new viral particles. Proviral DNA represents an archive of viral mutations that emerged through the course of a patient’s infection and may provide a historical record of the patient’s drug resistance mutations.
For patients with virologic suppression or low level viremia (e.g., less than 1,000 copies/mL), routine plasma RNA drug resistance testing may not be successful, because too little viral RNA is present to allow for amplification and sequencing. In contrast to HIV RNA, HIV proviral DNA remains present in a patient's cells even during virological suppression.
In certain cases, when RNA-based genotypic resistance testing is not possible, proviral DNA may be used to assess genotypic resistance. Several studies have presented data showing good concordance between proviral DNA resistance mutations and mutations detected in plasma RNA genotypes and/or related to previously administered antiretroviral drugs prior to virologic suppression.
Lübke et al investigated the concordance between viral plasma RNA and proviral DNA mutations in 48 treatment-naïve and 30 treatment-experienced patients.1 Among all drug resistance-associated mutations detected by either method, 75% were detected in both RNA and DNA, 23% were found exclusively in RNA, and 2% were found exclusively in proviral DNA.
Porter et al investigated the clinical utility of proviral DNA resistance analysis for virologically suppressed patients in the SPIRIT study to evaluate the safety and efficacy of switching to a rilpivirine/emtricitabine/tenofovir regimen.2 They found that 89% of occurrences of NRTI and NNRTI resistance-associated mutations reported by historical genotype were also detectable in proviral DNA.
Zaccarelli et al investigated proviral DNA resistance mutations in 149 virologically suppressed patients with 2 or more plasma RNA genotypes performed prior to virologic suppression.3 They found that 51% of patients had proviral DNA primary resistance mutations that were previously identified in plasma RNA. Primary resistance mutations that were mostly detected in proviral DNA were found to be related to previously administered antiretrovirals and/or to drugs with a low genetic barrier to resistance. Thus, proviral DNA resistance testing may be useful for detecting archived resistance mutations in the setting of low viral load when prior plasma RNA genotypes are not available.
Allavena et al performed proviral DNA resistance testing on 69 virologically suppressed patients with no history of virologic failure.4 They found that 88% of proviral protease mutations and 76% of proviral reverse transcriptase mutations were concordant with plasma RNA genotypes obtained prior to initiation of therapy.
Question 3. Can proviral DNA testing be used to guide regimen switches in virologically suppressed patients?
In some situations, yes. As noted in the 2016 International Antiviral Society USA (IAS USA) guidelines, “a proviral DNA genotype test may be helpful” for virologically suppressed patients being considered for a regimen change if their treatment and drug resistance history is not available.6
Several lines of evidence support this use. Proviral DNA tropism testing in virologically suppressed patients being evaluated for a switch to a CCR5 antagonist, which has been evaluated in a number of studies and used clinically for a number of years, is described here: https://education.questdiagnostics.com/faq/FAQ87. Studies have also shown good concordance of proviral DNA resistance testing with plasma RNA-based testing, as described in FAQ question 2 above.
In addition, Singh et al conducted a retrospective study of 140 patients who had access to a commercially available proviral DNA resistance test.5 Concordance with historical RNA genotypes was 72.5% for NRTI, 72.5% for NNRTI, and 76.8% for PI resistance-associated mutations. Of the 140 patients, 79 underwent an antiretroviral regimen change as a result of the proviral DNA test result. Supporting the utility of this approach, 85% of these patients maintained an undetectable viral load at 3 months post-therapy switch.
Question 4. Should proviral DNA resistance tests be used in patients with virologic failure?
Proviral DNA resistance tests should only be used in the setting of a low viral load. The DHHS guidelines and the 2016 IAS USA guidelines recommend obtaining a plasma RNA genotype in patients failing antiretroviral therapy.6,7 However, both guideline documents note that genotypic testing may be unsuccessful at low viral loads of between 500 and 1,000 HIV RNA copies/mL. The IAS USA guidelines suggest that if an RNA genotype cannot be obtained in this situation, “proviral DNA assays to estimate archived resistance may be considered.”6
Question 5. How do you perform proviral DNA resistance testing?
DNA is extracted from EDTA-whole blood, and the entire pol gene—including the protease (codons 1-99), reverse transcriptase (codons 1-560), and integrase (codons 1-288) regions—is amplified by polymerase chain reaction (PCR). The PCR product is then sequenced by next-generation sequencing (NGS), followed by bioinformatic analysis to filter out nonviable viral species and to identify resistance-associated mutations present in 10% or more of the viral species.
Question 6. How is predicted HIV drug resistance, based on proviral DNA, reported?
Predicted or probable resistance is reported for each NRTI, NNRTI, PI, and integrase inhibitor (INI). Resistance-associated mutations present in 10% or more of the viral species sequenced are reported. The HIV-1 viral subtype is also reported.
Question 7. Can I order both proviral DNA resistance and proviral DNA tropism testing?
Yes. In this circumstance use test code 94810(X), which provides a panel that includes both tests. 3 mL whole blood (minimum: 1.2 ml) is required. See https://education.questdiagnostics.com/faq/FAQ87 for more information on our proviral DNA tropism test.
Question 8. What are the sample requirements for proviral DNA resistance testing?
Please collect 2 mL (minimum 0.6 mL) whole blood in a lavender-top EDTA tube. If also ordering proviral DNA tropism testing as part of panel test code 94810(X), collect 3 mL (minimum 1.2 mL) whole blood.
Question 9. What are some of the limitations of the proviral DNA resistance test?
- The PCR primers used for proviral DNA resistance testing are able to amplify HIV-1 subtype B and many major non-B subtypes including A, C, BF, D, AE, AG, and H. Other non-B subtypes or HIV-1 strains with uncommon mutations may not be amplified in the assay.
Data on the clinical performance of proviral DNA resistance testing are still limited, and the clinical utility has yet to be fully established.6,7
- Some resistance mutations previously found in plasma viral RNA may no longer be detectable in proviral DNA.3,8,9
- Some archived resistance mutations may only be detectable in proviral DNA, and their clinical significance is not known.3,9,10 Although the “proviral DNA compartment” archives many resistance mutations that emerged throughout the course of infection, this archive should not be considered comprehensive. Cumulative plasma RNA genotypes may provide substantial additional information.11
- Lubke N, Di Cristanziano V, Sierra S, et al. Proviral DNA as a target for HIV-1 resistance analysis. Intervirology. 2015;58:184-189.
- Porter DP, Daeumer M, Thielen A, et al. Emergent HIV-1 drug resistance mutations were not present at low-frequency at baseline in non-nucleoside reverse transcriptase inhibitor-treated subjects in the STaR study. Viruses. 2015;7:6360-6370.
- Zaccarelli M, Santoro MM, Armenia D, et al. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. J Clin Virol. 2016;82:94-100.
- Allavena C, Rodallec A, Leplat A, et al. Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy. J Virol Methods. 2018;251:106-110.
- Singh H, Jones S, Vaamonde C, Wilkin T. Application of GenoSure archive in clinical practice. Open Forum Infect Dis. 2016;3(Suppl 1):1507.
- Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191-210.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 12/26/2017.
- Delaugerre C, Braun J, Charreau I, et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Medicine. 2012;13:517-525.
- Gantner P, Morand-Joubert L, Sueur C, et al. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. J Antimicrob Chemother. 2016;71:751-761.
- Falasca F, Montagna C, Maida P, et al. Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage regimen: 72-week follow-up. Clin Microbiol Infect. 2013;19:E318-321.
- Wirden M, Soulie C, Valantin MA, et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother. 2011;66:709-712.